UK Funding Nod For Novartis Migraine Drug After Bumpy Ride
Executive Summary
Following two previous rejections by the UK’s health technology assessment body and an appeal, Aimovig is now available on the National Health Service for preventing migraine.
You may also be interested in...
Netherlands Gives Funding Nod To CGRP Inhibitors For Chronic Migraines
The Dutch health technology appraisal body, ZIN, said Novartis’ Aimovig should be reimbursed for the treatment of chronic migraine after initially advising against it.
Disappointment For Novartis As England’s NICE Says No To Migraine Drug Again
New cost-effectiveness analyses and an improved deal for Aimovig have failed to change the health technology assessment body's mind about routine funding for the migraine prevention drug.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.